In this study, the health-related quality of life (HRQoL) of patients in the phase 3 CLEAR study are discussed. There were 355 patients on lenvatinib plus pembrolizumab; 357 patients on lenvatinib plus everolimus; and 357 patients on sunitinib in the CLEAR study. All were followed up for just over a year for quality of life assessments.
The CLEAR study had already shown that lenvatinib plus pembrolizumab improved the time to when the cancer started growing again and the treatment stopped working (progression-free survival) and overall survival time compared with sunitinib in patients with kidney cancer.
Health-related quality of life did not worsen for those patient on the combination treatment of lenvatinib pus pembrolizumab. Quality of life was either similar or better for patients treated with the combination compared with those who were treated with sunitinib alone.
Lenvatinib plus pembrolizumab shows better survival results compared with sunitinib, and does not affect the quality of life of the patients.